EU agency recommends remdesivir to treat COVID-19

Thursday, 25. June 2020 15:13

Gilead's remdesivir is recommended for European Union authorization as a drug that should be used to treat COVID-19 in patients older than 12, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use announced on Thursday.

The recommendation makes remdesivir the first drug backed by EMA for authorization. The agency added that it came to the decision after thoroughly examining a study sponsored by the United States National Institute of Allergy and Infectious Diseases (NIAID) and other studies of the drug.

EMA added that it has been in contact with the European Commission and that it expects the EU body to fast-track the approval of remdesivir.

Related Links: Gilead Sciences Inc.
Breaking the News / VP